Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia

NCT04263480 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

99

Enrollment

OTHER

Sponsor class

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG: Carfilzomib + Ibrutinib
DRUG: Ibrutinib

Sponsor

Christian Buske

Collaborators

[object Object]
[object Object]